Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.
A Japanese committee has provisionally approved the use of reprogrammed stem cells to treat diseased or damaged corneas. Researchers are now waiting for final approval from the health ministry to test the treatment in people with corneal blindness, which affects millions of people around the world.
Scientists from the Netherlands have received a €600,000 grant to test a treatment for osteoarthritis in humans that combines hydrogels and stem cells to help the knee joint heal.
High-risk stage two cancer patients could be identified more easily and accurately, due to a hopeful new prognostic method.
The US Food and Drug Administration (FDA) has approved Spravato (esketamine), a new nasal spray medication for treatment-resistant depression.
Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.
Bone elongation requires the maintenance of a growth plate of cartilage. Two studies have now identified stem cells specific to this structure that give rise to both cartilage cells and bone-marrow stem cells.
Hepatocellular carcinoma is the third leading cause of deaths from cancer worldwide. Infection with the hepatitis B virus is one of the leading risk factors for developing hepatocellular carcinoma, particularly in East Asia.
Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen’s favor upholding the validity of two Amgen patents related to PCSK9 antibodies.
AstraZeneca and MSD have announced positive results from the Phase III POLO trial, in which there was a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) for pancreatic cancer, making it the first PARP inhibitor to demonstrate benefit in the disease.